thallium has been researched along with aprepitant in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avkiran, T; Byrom, L; Gaffey, F; Jerman, J; Large, JM; Mathie, A; McCoull, D; Vaitone, E; Veale, EL; Walsh, Y; Wright, PD | 1 |
1 other study(ies) available for thallium and aprepitant
| Article | Year |
|---|---|
Aprepitant is a novel, selective activator of the K2P channel TRAAK.
Topics: Aprepitant; Cell Line; Humans; Ion Channel Gating; Neurokinin-1 Receptor Antagonists; Patch-Clamp Techniques; Potassium Channels; Receptors, Neurokinin-1; Structure-Activity Relationship; Thallium | 2022 |